Crinetics Pharmaceuticals, Inc. 8K

Crinetics Pharmaceuticals reported Q2 2026 results, highlighted by strong PALSONIFY revenue growth and a definitive agreement to be acquired by Vertex Pharmaceuticals for approximately $10.0 billion in cash, expected to close in Q3 2026.

Crinetics Pharmaceuticals, Inc. reported its second quarter 2026 financial results and business update, highlighted by the previously announced July 6, 2026 definitive agreement under which Vertex Pharmaceuticals Incorporated will acquire Crinetics for $85.00 per share in cash, valuing the equity at approximately $10.0 billion (about $8.8 billion net of estimated cash acquired), with closing expected in the third quarter of 2026 subject to customary regulatory and stockholder approvals. The company also disclosed strong initial commercial traction for its acromegaly drug PALSONIFY (paltusotine), generating $24.0 million in net product revenue for the quarter and contributing to total revenue of $25.1 million, alongside a net loss of $120.9 million and a cash, cash equivalents, and investment securities balance of $1.2 billion as of June 30, 2026. In addition, Crinetics announced that the FDA granted Rare Pediatric Disease Designation to its Phase 3 candidate atumelnant for classic congenital adrenal hyperplasia, and stated that, in light of the pending Vertex transaction, it is withdrawing previously issued guidance and will not host an earnings call for the quarter.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

8K

Source Type

fda

Accession

0001658247-26-000052

Alert Tier

8